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Organ sizea b s t r a c t
Organ size is controlled by the concerted action of biochemical and physical processes. Although
mechanical forces are known to regulate cell and tissue behavior, as well as organogenesis, the
precise molecular events that integrate mechanical and biochemical signals to control these pro-
cesses are not fully known. The recently delineated Hippo-tumor suppressor network and its two
nuclear effectors, YAP and TAZ, shed light on these mechanisms. YAP and TAZ are proto-oncogene
proteins that respond to complex physical milieu represented by the rigidity of the extracellular
matrix, cell geometry, cell density, cell polarity and the status of the actin cytoskeleton. Here, we
review the current knowledge of how YAP and TAZ function as mechanosensors and mechanotrans-
ducers. We also suggest that by deciphering the mechanical and biochemical signals controlling
YAP/TAZ function, we will gain insights into new strategies for cancer treatment and organ
regeneration.
 2014 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical
Societies. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/3.0/).1. Introducing YAP/TAZ and Hippo signaling network
1.1. The fast emergence of the Hippo signaling network – a brief
retrospective
Over the past 8 years, a new signaling pathway named Hippo
tumor suppressor pathway has emerged at an unprecedented
speed [1–3]. The orthology and high evolutionary conservation
among Drosophila ﬂy and mammalian genes, which encode the
main components of this pathway, were critical in facilitating the
fast pace of the discovery process [2]. The parallel delineation of
the Hippo pathway in genetically amenable Drosophila ﬂies and
mammalian models was, in a way, reminiscent of the successfuldeciphering of the Sevenless pathway, which regulates eye
development in the ﬂy and is orthologous to the growth regulating
epidermal growth factor pathway [4–6].
The rapid emergence of the Hippo pathway was further driven
by a wealth of published biochemical, structural and signaling
data that originated from an intense wave of research frequently
referred to as the ‘‘oncogene revolution’’ [7]. Here, a number of
well-deﬁned complexes were identiﬁed from among signaling
proteins, and their robust cellular and transcriptional ‘‘read-outs’’
were described in detail. Moreover, modular protein domains and
their cognate ligand motifs were characterized, at both functional
and structural levels, as regions of protein–protein interaction
[8,9]. Often, these structures were solved at a high atomic
resolution, which allowed for their use in modeling and simula-
tion studies. Subsequently ‘loss of function’ mutations were being
predicted and these predictions turned out to be useful for the
validation of various signals [9]. In more recent years, a plethora
of powerful transgenic mouse models became available that
allowed for genetic validation of data generated through cell-line
models.
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non-canonical
At its core, the mammalian Hippo pathway is composed of two
kinases, namely MST and LATS. They control the activity of two clo-
sely related transcriptional co-activators YAP and TAZ [2,9]. When
MST and LATS kinases respond to various upstream stimuli, the
MST-activated LATS kinase phosphorylates YAP and TAZ at a spe-
ciﬁc Serine residue located in the amino-terminal region of each
protein. Following this, 14-3-3 proteins recognize a signature motif
around the LATS-phosphorylated Serine, which allows strong pro-
tein–protein interactions to be established. The resulting complex
then ‘‘anchors’’ or sequesters YAP and TAZ within the cytoplasm
[2,10]. If the LATS kinase is inhibited, then YAP and TAZ enter the
cell nucleus and, after binding to TEA domain-containing transcrip-
tion factors known as TEADs, drive a transcription program of overt
proliferation [11]. YAP and TAZ themselves do not possess DNA-
binding activity.
Today, the Hippo pathway is referred to as the Hippo network
because it is subject to regulation by many membrane receptors,
including G protein-coupled receptors (GPCRs), LIF receptor [12],
E-cadherins [13]. Protein complexes of tight junctions and adher-
ens junctions also play a role, as does the polarity complex
‘Crumbs’, as well as the LATS kinase [14–16]. A current convention
among researchers of the Hippo network is that the regulation of
YAP/TAZ directly via LATS is called ‘‘canonical signaling’’. This is
in contrast to the term ‘‘non-canonical signaling’’, which has been
used in a number of recent reports to describe signaling scenarios
where YAP and TAZ are regulated independently of the LATS
kinase. Although this may represent an oversimpliﬁcation, the dis-
tinction remains useful, especially when discussing the Hippo net-
work in the context of mechanotransduction (Fig. 1).
1.3. YAP and TAZ are of intense interest to biologists and biopharma
YAP and TAZ are the focus of many laboratories because of their
remarkable roles in tissue homeostasis, organ development and
oncogenic transformation [1–3]. These transcriptional co-activa-
tors are potent oncogenes when overexpressed [2,17,18]. Unlike
other proto-oncogenes, YAP and TAZ are not usually mutated in
cancers. However, as a result of their ampliﬁcation or overexpres-
sion, or a lack of mechanisms that facilitate their cytoplasmic
retention, the YAP and TAZ proto-oncogenes are often converted
into potent oncogenes [1,17]. Biopsy screening from a number of
cancers indicated that preferential nuclear localization of YAP/
TAZ, or overall increased expression of YAP/TAZ in both the nucleus
and the cytoplasm, is associated with a poor prognosis and reduced
survival rate [1,19].
Several cancers, including liver cancer, frequently harbor an
ampliﬁcation of the YAP gene as part of the 11q22 amplicon [17].
Organ-speciﬁc overexpression of YAP in mice causes excessive
organ growth. This is particularly relevant when the protein is
overexpressed in the liver, as chronic overexpression in this organ
results in hepatocellular carcinoma [2,17,18]. When expressed as
transgenes in other mouse organs, YAP and TAZ impair differenti-
ation, while increasing the content of stem and progenitor cells [3].
The main transcriptional target of YAP and TAZ is the TEAD fam-
ily of transcription factors. These drive the expression of prolifera-
tive genes, as well as genes encoding inhibitors of apoptosis [11].
Libraries of small molecules have been screened for compounds
that disrupt the YAP/TAZ-TEAD interface and attenuate the onco-
genic function of YAP/TAZ [20,21]. Among successful ‘‘hits’’ is Ver-
teporﬁn, a benzoporphyrin derivative, which is an approved drug,
used clinically to treat macular degeneration [20]. Dobutamine is
another drug that was shown to expel YAP from the cell nucleus
[21]. More recently, PDZ motif-binding compounds wereconsidered as potential inhibitors of YAP/TAZ nuclear transloca-
tion, and therefore inhibitors of their oncogenic activity [22]. It is
expected that in the near future, new cancer drugs targeting the
YAP/TAZ effectors will be identiﬁed, and tested preferentially in
patients who harbor cancers with ampliﬁed or overexpressed
YAP/TAZ genes. Innovative cancer drugs will most likely be devel-
oped based on the new insights we are gaining now from studying
YAP/TAZ as mechanosensors and mechanotransducers.
1.4. Surprising ﬁndings illuminate the role of YAP/TAZ in contact
inhibition of proliferation
Contact inhibition of proliferation (CIP) is a feature of a cell’s
normal ‘‘social’’ behavior [23]. CIP is deregulated in cancer and this
is one of the major hallmarks of the neoplastic transformation of
cells [23]. Interestingly, two laboratories have implicated YAP/
TAZ in the CIP process. The team of Kun-Liang Guan has shown that
in sparsely populated cells, YAP and TAZ remain in the nucleus
where they drive proliferation. In densely populated cells, how-
ever, where contact between cells is maintained, YAP and TAZ
are inactivated and localized in the cytoplasm [24]. The team of
Stefano Piccolo added a new facet to the understanding of the
Hippo network by reporting, in two notable publications [25,26],
that a stiff matrix substrate will activate YAP and TAZ, and promote
their nuclear localization, whereas a soft matrix surface would
inactivate them, and promote their cytoplasmic retention. These
conditions ultimately promoted or limited growth, respectively.
Moreover, the Piccolo lab provided strong evidence that the status
of the F-actin cytoskeleton, and Rho GTPase function, underlies the
regulation of YAP/TAZ. It was shown that this regulation could also
be LATS independent, i.e., non-canonical Hippo signaling [25].
These three reports have strongly reverberated in the signaling
ﬁeld because, intuitively, they provided clues into the mechanism
of CIP, the control of organ size and the genesis of cancer. More
importantly these reports highlighted that mechanobiology is an
important facet of cancer signaling. Intriguingly, YAP/TAZ not only
function as effectors of CIP, but they also act as a rheostat to regu-
late the nuclear localization and function of the phosphatase SHP2
under different cell densities [27].2. Mechanotransduction and the role of YAP/TAZ at the cell level
Organs and cells are constantly subjected to mechanical stres-
ses. Examples of such stresses are: the force of skeletal muscle con-
traction, a ﬂow-induced shear stress in circulatory systems, the
stretching, strain, compression and pressure arising from different
stiffness of extracellular matrices and the geometry of cells. Within
cells, the intracellular force/tension generated by the actin-myosin
cytoskeleton, as well as the surface tension generated at the mem-
brane, provide intrinsic mechanisms to sense and respond to phys-
ical perturbations. Indeed, the classic ﬁnding of mesenchymal stem
cells developing into speciﬁc cell lineages as a function of substrate
stiffness, and different tissues and organs adopting distinct physi-
cal niches for their differentiation, all highlight that in addition to
biochemical signals, the physical environment controls cell fates
and organ formation [28–30].
At the molecular level, cells can sense external mechanical sig-
nals through various contact points. These contact points include
stretch-modulated ion channels, integrin based cell-matrix (focal)
adhesions and cell–cell junctions and contacts [31–36]. Upon sens-
ing force, cells react by generating equal but opposite forces by
modulating myosin motor activity to balance the tension in the
actin cytoskeleton [37–39]. External forces may trigger active
changes in the actin cytoskeleton. For example, cell stretching
can lead to sustained activation of RhoA and myosin and
Fig. 1. Schematic representation of the canonical and non-canonical Hippo signaling pathways. (A) In the canonical Hippo signaling pathway, junctional complexes, polarity
complexes, G-protein coupled receptors (GPCRs) or leukemia inhibitory factor (LIF) initiate their signals upon cell–cell contact, polarization of epithelial cells or ligand-
receptor association. These signals result in the activation of MST kinase (Hippo kinase ortholog), which phosphorylates and activates LATS kinase. In turn, LATS kinase
inhibits the activity of YAP/TAZ by Serine phosphorylation. This traps YAP/TAZ in the cytoplasm (by 14-3-3), at the apical cell membrane (by Scribble, Scrb), at adherens
junctions (by 14-3-3 and catenins), or at the apical tight junction (by the polarity complex Crumbs and Angiomotins, i.e. AMOT). Note that certain ligands for GPCR inactivate
LATS instead. (B) In contrast, non-canonical modes of the Hippo signaling pathway does not involve MST/LATS to act on YAP/TAZ directly. Instead, they involve either an
unknown serine kinase (X-KINASE) that has the ability to phosphorylate YAP and TAZ on the same Serine as LATS kinase. Alternatively, YAP/TAZ is inhibited by a non-kinase
mechanism, shown by the AMOT protein. AMOT binds F-actin ﬁlaments and allows YAP to enter the nucleus. However, upon actin de-polymerization AMOT dissociates from
actin and traps YAP/TAZ in the cytoplasm through a strong complex that is mediated by WW domains and PPxY motifs. When phosphorylated by LATS, AMOT can also recruit
ubiquitin ligase to the AMOT/YAP complex and target YAP for degradation. Another example of non-canonical regulation of YAP is through the shuttling of a tight junction
protein ZO-2 together with YAP to the nucleus where it suppresses YAP activity. On the contrary, the p130 isoform of AMOT promotes nuclear localization of YAP and acts as a
transcriptional cofactor of the YAP-TEAD complex. This ternary complex drives the transcription of TEAD target genes for cell proliferation. On the other hand, Rho GTPases
could control YAP/TAZ activity through canonical (e.g. GPCR-linked) or non-canonical arms of Hippo signaling (e.g. focal adhesion-linked). For clarity, only YAP was included
in this signaling scheme, omitting TAZ. However, in most signaling events, YAP/TAZ could be indicated. Icons representing signaling proteins that were not discussed in the
text in detail are shown in italics and in gray color. Please refer to the main text for more details.
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Moreover, it is well known that contractility forces are able to reg-
ulate gene expression [43], development [44,45], cell proliferation
[46], differentiation [47] and migration [48].
2.1. Substrate rigidity and the extracellular matrix (ECM)
The subcellular localization and activity of YAP/TAZ are tightly
regulated by cell substrate rigidity and topography [15,16,25],
actin cytoskeleton remodeling [26,49,50], and by speciﬁc regimens
of cell stretching [26]. These observations directly highlight that
YAP and TAZ may serve as novel mechanotransducers and mech-
naosensors (Table 1). As reported by the Piccolo laboratory, sub-
strate rigidity tightly controls the subcellular localization of YAP/
TAZ. When cells are grown on a soft matrix (circa 0.7 kPa), YAP/
TAZ localize to the cytoplasm, whereas when cells are grown on
a hard matrix (circa 40 kPa), YAP/TAZ localize to the nucleus and
drive the transcription of proliferative genes [25]. In addition to
regulating the subcellular localization of YAP/TAZ, substrate
rigidity may also control their expression in some cells. Differential
substrate stiffness was shown to modulate the expression of YAP/
TAZ in human trabecular meshwork cells [51]. Interestingly, the
expression of YAP/TAZ was upregulated in these cells when grown
on 75 kPa hydrogel as compared to 5 kPa hydrogel.
Importantly, the notion that the subcellular localization of YAP/
TAZ is controlled by substrate stiffness, can also apply to 3D cul-
tures. Mammary epithelial cells seeded onto a 3D soft matrix tend
to form growth-arrested acini with YAP/TAZ being localized in the
cytosol. In contrast, when these cells grow on a stiff matrix, larger
spheroids with tubules and organoid-like structures are observed
with YAP localized to the nucleus [26]. Overall, the dynamic shut-
tling, transcriptional activity of YAP/TAZ and in some cases the
expression of YAP/TAZ, are tightly linked to matrix stiffness.
Although our understanding of the underlying mechanism is still
nebulous, new ﬁndings have begun to provide clues into how the
F-actin cytoskeleton acts as a critical intermediary between
mechanical cues from the ECM and the control of YAP/TAZ activity.
Cells are not simply regulated by the ECM in a ‘‘passive’’ man-
ner. They remodel the ECM by secreting collagen to promote
matrix stiffening. Such changes in ECM stiffness provide further
mechanical signals for cells to adapt to their environment. Dereg-
ulation of such processes leads to pathological abnormalities. For
instance, many cancers, such as breast cancer, are associated with
the development of tumor masses that are more rigid than their
surrounding tissue. This has been attributed to an altered compo-
sition of the ECM. By softening the tumor microenvironment one
can actually attenuate the growth and progression of the tumor
[52]. Intriguingly, remodeling of the ECM is in part dependent on
the activity of YAP. The activation of YAP in cancer-associated
ﬁbroblasts (CAFs) promotes matrix stiffening through an extensive
deposition of collagen [50]. Such matrix stiffening in turn creates
tension within CAFs, leading to the activation of Src kinase and
the nuclear translocation of YAP. Consequently, YAP (and possiblyTable 1
Mechanical factors that inﬂuence YAP/TAZ activity.
Treatment Impact on YAP/TAZ References
Stretching YAP/TAZ enters the nucleus in
contact-inhibited cells upon stretching
[26]
Geometry YAP/TAZ re-localizes to cytoplasm on
small surface area
[25,26,56]
Cell density YAP/TAZ localizes to cytoplasm in
contact-inhibited cells
[24,26,62]
Substrate rigidity YAP/TAZ re-localizes to cytoplasm on soft
substrate matrix. Expression of YAP/TAZ is
upregulated on hard substrate matrix
[25,51]TAZ) promotes the expression of cytoskeletal regulators, such as
ANLN and DIAPH3, and stabilizes actomyosin proteins. This leads
to further matrix stiffening, thereby establishing a self-enhancing
loop during tumorigenesis. This may explain why organ speciﬁc
overexpression of YAP in transgenic mice initially causes hypertro-
phy, but gradually leads to cancer. In this scenario, prolonged
expression of the YAP transgene, and the ensuing changes in the
ECM, may promote a metastatic phenotype.
2.2. Strain forces and YAP/TAZ
The inﬂuence of strain force on cells was recently outlined in an
elegant study by LeGoff et al. which analyzed ‘‘endogenous’’ cell
stretching. In this study, the authors unveiled the global pattern
of mechanical stresses that polarize cell divisions and cell shape
in growing Drosophila wing discs [53]. By supplementing an inno-
vative quantitative approach with computer modeling, they
showed that cells in the periphery of the tissue are mechanically
stretched while the inner cells are compressed. Remarkably, a per-
turbation of the Hippo signaling pathway was shown to result in
an overgrowth of the tissue, speciﬁcally from induced tissue strain
and cell position-dependent changes in proliferation [53]. It was
proposed that this may be important in the regulation of cellular
behavior during organogenesis. In connection to this, phosphory-
lated active ERK1/2 (nuclear effector for proliferation) was
observed at the periphery but not in the inner layer of zebraﬁsh
liver [54]. This suggests that mechanical strain and stress can reg-
ulate the function of nuclear effectors.
CIP restricts the proliferation of cells by activating Hippo to
ensure that YAP/TAZ is inactive and localized in the cytosol [24],
however, it remains unclear if mechanical forces play a role in
CIP. While investigating this very point, the Piccolo laboratory
demonstrated that mechanical stretching can indeed induce the
entry of YAP/TAZ into the nucleus to stimulate proliferation of con-
tact-inhibited mammary epithelial cells [26]. This implied that an
external strain force can overcome YAP/TAZ inhibition in growth
arrested, contact-inhibited cells. This seemingly simple observa-
tion, where mechanical stretching was able to override CIP via
YAP/TAZ, is of paramount importance. If the precise mechanism
behind this regulation is deciphered, it will provide a rationale
for the development of new tools to facilitate organ regeneration
and manage cancer. A simple hypothesis that may explain the
effect of stretching the cell monolayer is that YAP/TAZ could be
activated after the integrity of cell–cell junctional complexes is
modulated. Being directly connected to these junctional com-
plexes, the F-actin cytoskeleton would be critically involved in this
process.
2.3. Cell geometry and YAP/TAZ
The wide diversity in cell geometries reﬂects the assortment of
cellular morphologies that arise during tissue and organ morpho-
genesis, remodeling and planar polarization. It is known that cell
proliferation can be regulated by changes in cell geometry and
YAP/TAZ sense these changes [39,55]. For example, single cells pla-
ted on a small adhesive micro-patterned surface (300 lm2) will
assume a more bulky geometry with YAP/TAZ localized in the
cytoplasm, while single cells plated on a large adhesive micro-pat-
terned surface (10,000 lm2) will have ‘ﬂattened’, epithelial cell-
like geometry with active YAP/TAZ localized in the nucleus
[25,26]. This observation was replicated in a study conﬁrming that
YAP was mostly cytoplasmic in cells spread on a small surface area
but distinctly localized in the nucleus in cells spread on a large sur-
face area [56]. How YAP/TAZ sense changes in the cell geometry is
not known. It is possible that adhesion sites, and their associated
F-actin cytoskeleton, are affected differently in rounded cells
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may exist that begin to explain how YAP/TAZ sense cell geometry.
It is important to note here that cell geometry also imposes a phys-
ical constraint on the structure of the nucleus, as well as on the
organization of chromatin. It can also affect the activity of some
chromatin remodeling enzymes [57,58]. Whether or not YAP/TAZ
activity could indeed be modulated by nuclear and adhesion
mechanics remains to be established.
3. Mechanosensing and intracellular signals
3.1. Actin integrity and Acto-myosin contractility
Myosin motor proteins cross-link and slide along actin ﬁla-
ments to generate contractile forces and tension in cells. Recent
studies have demonstrated that such tensile forces are important
in regulating the activity of YAP/TAZ. For example, the role of
YAP/TAZ in sensing differences in substrate stiffness is dependent
on the tension of the actin cytoskeleton [25]. This was shown by
treating cells grown on a rigid substrate with Blebbistatin, an
inhibitor of non-muscle myosin II. Here, not only was the intracel-
lular tension released, but YAP/TAZ re-localized from the nucleus
to the cytosol. Besides the tensile strength, the actual integrity of
the actin cytoskeleton can also regulate the activity of YAP/TAZ.
For example, treatment of cells with Latrunculin A, an inhibitor
of actin polymerization, results in cytosolic localization of YAP/
TAZ [25], increased phosphorylation of YAP at Serine 127 and
decreased expression of CTGF; a target gene of YAP/TAZ [51]. In
contrast, F-actin regulates the activity of YAP in a LATS-dependent,
i.e., canonical manner [49,56]. Extensive polymerization of actin
will inactivate Hippo (MST ortholog in Drosophila) and subse-
quently allow Yki (YAP ortholog) to go to the nucleus to drive pro-
liferation. Interestingly. Aragona et al. demonstrated that the
presence of actin modulating proteins such as Coﬁlin, CapZ and
Gelsolin regulate YAP/TAZ activity and maintain growth arrest in
contact inhibited cells [26]. For example, when CapZ was depleted,
contact inhibition of cell proliferation was derepressed and cells
started to proliferate.
Alternative pathways also exist to regulate YAP/TAZ activity.
For example, when cells are grown on stiff substrate, RhoA, which
is an activator of F-actin cytoskeleton and actomyosin contractility,
regulates YAP/TAZ activity independently of LATS activity [25]. Dif-
ferent signals from G-protein coupled receptors (GPCRs) can also
modulate LATS activity to varying degrees. For example, lysophos-
phatidic acid stimulates Ga12/13-coupled receptor to induce YAP/
TAZ activity by inhibiting LATS, whereas Gas-coupled signals
activate LATS, thus inhibiting YAP/TAZ [14] (Fig. 1A). The Ga12/13-
induced YAP/TAZ activation can be blocked by the F-actin disrupt-
ing agent, Latrunculin A [14], suggesting that GPCRs and RhoA act
upstream of LATS to regulate YAP/TAZ. Another study by Zhao
et al., demonstrated that cytoskeletal reorganization caused by cell
detachment can activate anoikis through the Hippo pathway to
induce cell death [59].
RhoA and YAP/TAZ were also implicated in the mechanism by
which statins affect cell signaling [60]. In this recent study, statins,
which are very popular cholesterol-lowering drugs that target
HMG-CoA-reductase, were shown to inhibit nuclear translocation
of YAP/TAZ. This inhibition was further potentiated by the inhibi-
tion of RhoA [60]. The RhoA-mediated increase in YAP/TAZ phos-
phorylation was LATS independent, suggesting an unknown
kinase is involved in mediating non-canonical signaling by Hippo.
It should be noted that the doses of statins used in the reported cell
culture studies signiﬁcantly exceeded the recommended therapeu-
tic doses for individuals undergoing cholesterol-lowering thera-
pies. Thus, the overt effects of statins on YAP and TAZ observedmay be minimal and not affect the stem and progenitor cells that
control organ homeostasis.
There has also been genetic validation of the crosstalk between
‘contractility’ and the function of YAP. Helen McNeill and
colleagues [61] have shown, for example, that kidney-speciﬁc con-
ditional knockout of the YAP in mice results in a defective organ
with abnormal glomeruli, ducts without lumen, and therefore
empty bladders. Interestingly, the kidney-speciﬁc knockout of
another gene, Cdc42, which encodes a small GTPase of the Rho fam-
ily, phenocopied the YAP knockout. This result strongly suggests
that CDC42 and YAP function in the same pathway and support
the signaling interface between actin polymerization and YAP, at
least in the kidney. Taken together, these biochemical and genetic
data strongly support an intricate link by which the actin cytoskel-
eton network regulates YAP/TAZ signaling (Fig. 2).
3.2. Signaling by scaffold proteins at cell–cell contacts, and the role
of AMOT
Cell–cell contacts are crucial in the maintenance of the apical-
basal polarity of epithelial cells, and to mediate CIP. Generally, cell
adhesions experience high compression and tensile forces. Several
signaling components of the Hippo network, including Merlin,
Kibra, as well as YAP/TAZ, have been reported to localize at the api-
cal membrane. There they may serve as sensors of mechanical ten-
sion through the status of polarity and the integrity of junctional
complexes. In addition, various junctional proteins such as a-
and b-catenins, Crumbs polarity complex [62], Angiomotins
(AMOTs) [62–67] and Zonula Occludens proteins can physically
interact with YAP/TAZ and regulate its activity [67,68] (Fig. 1A
and B). Many of these proteins, including Scribble also serve as
scaffolds that direct the precise placement of various components
of the Hippo network in order to achieve a versatile crosstalk in
signaling [69]. For example, a-catenin is a component of adherens
junctions that mediates cell–cell contact and couples the adhesion
complex to the actin cytoskeleton. Several studies have shown that
in the epidermis, a-catenin negatively regulates YAP by localizing
the phosphorylated YAP-14-3-3 complex to adherens junctions
[70,71]. Furthermore, in densely-packed cells, Crumbs, which is a
trans-membrane polarity complex, is known to couple cell density
sensing to the activation of the Hippo pathway and the inactivation
of YAP [62]. This process is mediated by another regulator of YAP,
AMOTs, which forms a canonical Hippo core complex with MST
and LATS (Fig. 1A).
Another protein that predominately functions at cell–cell adhe-
sion sites, yet was also shown to interact with YAP/TAZ, is Zona
Occludens 2 (ZO-2). It was suggested that this protein facilitates
the shuttling of YAP/TAZ between junctional complexes and the
cytoplasm as well as between the cytoplasm and the cell nucleus
[67,68,72]. A complex reportedly resulted from interactions
between the ﬁrst PDZ domain of ZO-2 and a conserved carboxy-
terminal motif on YAP/TAZ [68,72]. When ZO-2 was overexpressed
and forced into the cell nucleus, it attenuated proliferative activity
of YAP in MDCK cells (Fig. 1B). The discovery of a YAP/TAZ/ZO-2
complex was interesting as it provided a lead for the investigation
into the role of tight junction proteins in the direct regulation of
the transcriptional activity of YAP/TAZ. We hope to investigate this
signaling further using mouse models that harbor mutations of
YAP/TAZ and ZO genes.
The scaffold protein Scribble also plays an important role in the
Hippo signaling network. This protein can assemble MST and LATS
kinases together with TAZ, independently of the known Hippo
scaffolding protein Salvador. Scribble assembles the complex at
the apical cell membrane, thereby promoting the activation of
LATS by MST kinase, which subsequently inactivates TAZ [73]. Like
Fig. 2. YAP/TAZ effectors as mechanosensors and mechanotransducers. (A) It is hypothesized that the presence of F-actin and stress ﬁbers is critical for the activation of YAP
and TAZ. When translocated to the nucleus, they associate with TEAD transcription factors to drive transcription of proliferative genes. Rho GTPases and actin modiﬁers such
as CAP-Z, Coﬁlin and Gelsolin can affect F-actin network stability and directly or indirectly regulate YAP/TAZ translocation to the nucleus (please see Fig. 1 and text for
details). Although increasing amount of data support the impact of physical perturbation on YAP/TAZ function (as summarized in Table 1), our main challenge now is to
achieve a detailed understanding of the concerted roles of F-actin, actin regulators and Hippo-YAP signaling in response to various physical cues. These include stretching and
strain, compression and expansion, membrane tension and shear stress as well as different topography, cell density, cell–cell contacts, extracellular matrix/substrate stiffness
and cell geometry which can be experimentally controlled by micro-patterned area (B).
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does so in a canonical as well as non-canonical fashion [63–65].
AMOT is a notable signaling partner of YAP/TAZ, and is of partic-
ular interest because of its ability to bind both actin and adhesion
complexes (Fig. 1B) [74–76]. In its cytoplasmic form, AMOT can
promote phosphorylation of YAP and induce its cytoplasmic reten-
tion by forming a stable complex with YAP/TAZ. This ultimately
reduces the transcription of YAP/TAZ target genes such as CTGF
and Cyr61 [63,64,66]. Importantly for our discussion, like YAP/
TAZ, AMOT is also phosphorylated by LATS kinase. This leads to
the dissociation of AMOT from actin and to the inhibition of cell
proliferation [76–78] as YAP activity is suppressed via the recruit-
ment of 14-3-3 and ubiquitin ligase AIP4 [79]. Such a ternary com-
plex can stabilize AMOT and promote the ubiquitination and
degradation of YAP, thus leading to the suppression of cell growth.
As such, AMOT serves as an anchor of YAP/TAZ, to ensure these
effectors are retained in the cytoplasm through WW domain-PPxY
link-mediated complexes [9]. This function is redundant with
14-3-3 proteins.
Importantly, AMOT is present in cells at relatively high concen-
trations and its binding to YAP/TAZ is of high afﬁnity. Immunopre-
ciptation of YAP or TAZ, even in ‘‘harsh buffers’’, which contain SDS
detergent and high concentrations of salt, are known to pull down
AMOT or one of the members of the AMOT family of proteins, in a
stoichiometric complex [67]. When AMOT is engaged in a complexwith F-actin, YAP/TAZ may be free to enter the cell nucleus and be
active. We suggest that AMOT, and members of the family of AMOT
proteins, play an important role in conveying the status of the
F-actin cytoskeleton to YAP/TAZ, through competitive binding
between F-actin and YAP/TAZ. Thus, increased polymerization of
the F-actin cytoskeleton could lower AMOT levels, releasing YAP/
TAZ to travel to the nucleus and activate cell proliferation
(Fig. 1B). Surprisingly, besides its role in the cytoplasm, one iso-
form of AMOT, AMOT-130 can promote the nuclear localization
of YAP and act as a transcriptional cofactor of YAP-TEAD to drive
the transcription of YAP target genes [80]. It remains unclear if
such a complex can be regulated upon mechanical stress or upon
contact inhibition.
4. Concluding remarks
Despite the fast progress in the ﬁeld, we still do not know how
YAP and TAZ work in concert with the complex mechanical milieu
to regulate organ size. From the large sets of data in systems biol-
ogy, we appreciate that in addition to the Hippo signaling network
multiple other pathways play important roles in the organ homeo-
stasis; these including the mTOR pathway, the WNT pathway and
several other major signaling pathways [81]. Although YAP and
TAZ can play dominant roles in organ size control they can also
function as potent oncogenes in certain organs. We do not
B.C. Low et al. / FEBS Letters 588 (2014) 2663–2670 2669understand why cancer develops in those organs after transgenic
overexpression of YAP/TAZ genes, since both mechanical and bio-
chemical factors could be important. However, modern tools of
mechanobiology together with ﬁne ‘‘omic’’- and systems biology-
based approaches, should enable dissection of the functions of
YAP and TAZ in the background of other signaling pathways
involved in organ size control. Once we decipher the mechanical
and biochemical signals that control the function of YAP and TAZ,
we will then gain further insights to new strategies for modulating
cell growth in cancer treatment, tissue regrowth or organ
regeneration.
This review is meant to stimulate discussion in the exciting
research area that literally ‘‘exploded’’ in the span of the past three
years at the interface of cancer signaling and mechanobiology. We
hope that the precise mechano-molecular signaling that underlies
organ size control will be soon deciphered. We believe that para-
digm-shifting discoveries are imminent in this area of research
because of the need for interdisciplinary observations of both
mechanical and biochemical changes. Deregulation of organ size
control results in many pathologies, including cancer. Therefore,
an understanding of these controls at the molecular and organis-
mal level holds the promise of better public health.
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